Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 8, 2010

iPierian Secures $22M to Bolster iPSC-Based Drug Discovery

  • iPierian, a company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, closed a $22 million Series B equity financing. The money will allow the company to drive its programs into the clinic while securing pharmaceutical partnerships.

    “The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will dramatically improve the drug discovery and development process,” according to Krishna Yeshwant, M.D., partner at Google Ventures, which was one of the new investors for this round. Dr. Yeshwant will join the iPierian board of directors.

    The Series B funding brings the total amount of equity capital raised by iPierian to $54 million since its inception in 2007. The company is developing and applying cellular reprogramming and differentiation technologies to harness the power of pluripotent stem cells for the discovery and development of small molecules or biologics.

    Its initial focus is on neurodegenerative diseases including spinal muscular atrophy, amyotrophic lateral sclerosis, and Parkinson disease. In addition, iPierian has a therapeutic program intended for partnering in metabolic disease.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »